New York State Common Retirement Fund bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,897 shares of the company's stock, valued at approximately $894,000. New York State Common Retirement Fund owned 0.08% of Establishment Labs at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP purchased a new position in shares of Establishment Labs in the fourth quarter valued at $27,000. Federated Hermes Inc. boosted its stake in shares of Establishment Labs by 3.0% in the fourth quarter. Federated Hermes Inc. now owns 32,720 shares of the company's stock valued at $1,507,000 after purchasing an additional 953 shares during the period. Swiss National Bank boosted its stake in shares of Establishment Labs by 2.7% in the fourth quarter. Swiss National Bank now owns 38,500 shares of the company's stock valued at $1,774,000 after purchasing an additional 1,000 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Establishment Labs in the fourth quarter valued at $161,000. Finally, Hood River Capital Management LLC boosted its stake in shares of Establishment Labs by 236.4% in the fourth quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock valued at $273,000 after purchasing an additional 4,160 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. Mizuho upped their price target on shares of Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Citigroup upped their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a report on Wednesday, July 9th. BTIG Research assumed coverage on shares of Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target on the stock. Wall Street Zen raised shares of Establishment Labs from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $54.83.
Read Our Latest Report on ESTA
Establishment Labs Stock Down 1.7%
Shares of NASDAQ:ESTA opened at $42.41 on Friday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -13.68 and a beta of 0.80. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $50.85. The company's fifty day moving average is $39.91 and its two-hundred day moving average is $36.79. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. The company had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The firm's revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.58) earnings per share. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.
Establishment Labs Profile
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.